GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of Galadus score

Published on Mar 1, 2019in Cancer Epidemiology, Biomarkers & Prevention4.344
· DOI :10.1158/1055-9965.EPI-18-0281
Ju Dong Yang32
Estimated H-index: 32
(Mayo Clinic),
Benyam D. Addissie7
Estimated H-index: 7
(Mayo Clinic)
+ 28 AuthorsLewis R. Roberts84
Estimated H-index: 84
(Mayo Clinic)
Sources
Abstract
Background/Aim: The GALAD score is a serum biomarker-based model that predicts the probability of having hepatocellular carcinoma (HCC) in patients with chronic liver disease. We aimed to assess the performance of the GALAD score in comparison to liver ultrasound for detection of HCC. Methods: A single center cohort of 111 HCC and 180 controls with cirrhosis or chronic hepatitis B and a multicenter cohort of 233 early HCC and 412 cirrhosis patients from the Early Detection Research Network (EDRN) Phase 2 HCC Study were analyzed. Results: The area under the ROC curve (AUC) of the GALAD score for HCC detection was 0.95 [95% confidence interval (CI): 0.93-97], which was higher than the AUC of ultrasound (0.82, P<0.01). At a cut off of -0.76, the GALAD score had a sensitivity of 91% and a specificity of 85% for HCC detection. The AUC of the GALAD score for early stage HCC detection remained high at 0.92 [95%CI: 0.88-0.96] (cut off -1.18, sensitivity 92%, specificity 79%). The AUC of the GALAD score for HCC detection was 0.88 (95% CI, 0.85-0.91) in the EDRN cohort. The combination of GALAD and ultrasound (GALADUS score) further improved the performance of the GALAD score in the single center cohort, achieving an AUC of 0.98 [95%CI: 0.96-0.99] (cut off -0.18, sensitivity 95%, specificity 91%). Conclusions: The performance of the GALAD score was superior to ultrasound for HCC detection. The GALADUS score further enhanced the performance of the GALAD score. Impact: The GALAD score was validated in the US.
Download
📖 Papers frequently viewed together
201410.50PLOS Medicine
3 Authors (Amit G. Singal, ..., Jasmin A. Tiro)
389 Citations
716 Citations
201724.80JAMA Oncology
10 Authors (So Yeon Kim, ..., Yung Sang Lee)
113 Citations
References31
Newest
#1Christina Fitzmaurice (UW: University of Washington)H-Index: 43
#1Christina Fitzmaurice (UW: University of Washington)H-Index: 7
Last. Mohsen Naghavi (UW: University of Washington)H-Index: 142
view all 186 authors...
Importance Cancer is the second leading cause of death worldwide. Current estimates on the burden of cancer are needed for cancer control planning. Objective To estimate mortality, incidence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 32 cancers in 195 countries and territories from 1990 to 2015. Evidence Review Cancer mortality was estimated using vital registration system data, cancer registry incidence data (transformed to mor...
3,000 CitationsSource
#1Peter R. Galle (University of Mainz)H-Index: 28
#2Alejandro Forner (European Organisation for Research and Treatment of Cancer)H-Index: 1
Last. Valérie VilgrainH-Index: 95
view all 8 authors...
Summary Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
4,706 CitationsSource
#1Ju Dong Yang (Mayo Clinic)H-Index: 32
#2Ajitha Mannalithara (Stanford University)H-Index: 21
Last. W. Ray Kim (Stanford University)H-Index: 70
view all 7 authors...
Surveillance for hepatocellular carcinoma (HCC) has been recommended in patients with cirrhosis. In this work, we examine the extent to which the competing risk of hepatic decompensation influences the benefit of HCC surveillance, by investigating the impact of availability of liver transplantation (LTx) and rate of progression of hepatic decompensation on survival gain from HCC surveillance. A multistate Markov model was constructed simulating a cohort of 50-year old patients with compensated c...
28 CitationsSource
#1Ju Dong Yang (Mayo Clinic)H-Index: 32
#2Jianliang Dai (University of Texas MD Anderson Cancer Center)H-Index: 9
Last. Lewis R. Roberts (Mayo Clinic)H-Index: 84
view all 15 authors...
Background: The utility of alpha-fetoprotein (AFP) for hepatocellular carcinoma (HCC) surveillance is controversial. We aimed to identify factors associated with elevated AFP and define the patients for whom AFP is effective for surveillance. Methods: Data from the NCI Early Detection Research Network phase II HCC biomarker study (233 early-stage HCC and 412 cirrhotic patients) were analyzed. We analyzed 110 early-stage HCC and 362 cirrhotic hepatitis C virus (HCV) patients for external validati...
24 CitationsSource
#1Masao Omata (UTokyo: University of Tokyo)H-Index: 128
#2Ann-Lii Cheng (NTU: National Taiwan University)H-Index: 90
Last. Shiv Kumar SarinH-Index: 93
view all 21 authors...
Abstract There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia-Pacific region, where HCC is one of the leading public health problems. Since the "Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines" meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. ...
709 CitationsSource
#1Omair Atiq (UTSW: University of Texas Southwestern Medical Center)H-Index: 3
#2Jasmin A. Tiro (UTSW: University of Texas Southwestern Medical Center)H-Index: 33
Last. Amit G. Singal (UTSW: University of Texas Southwestern Medical Center)H-Index: 62
view all 9 authors...
Although surveillance ultrasound and alpha fetoprotein (AFP) tests have minimal direct harm, downstream harms from follow-up tests must be weighed against surveillance benefits when determining the value of hepatocellular carcinoma (HCC) screening programs. Our study's aims were to characterize prevalence and correlates of surveillance benefits and harms in cirrhosis patients undergoing HCC surveillance. We conducted a retrospective cohort study among patients with cirrhosis followed at a safety...
98 CitationsSource
#1O. Simmons (Parkland Health & Hospital System)H-Index: 1
#2David T. Fetzer (UTSW: University of Texas Southwestern Medical Center)H-Index: 13
Last. Amit G. Singal (Parkland Health & Hospital System)H-Index: 62
view all 9 authors...
SummaryBackground Abdominal ultrasound fails to detect over one-fourth of hepatocellular carcinoma (HCC) at an early stage in patients with cirrhosis. Identifying patients in whom ultrasound is of inadequate quality can inform interventions to improve surveillance effectiveness. Aim To evaluate and identify predictors of ultrasound quality in patients with cirrhosis. Methods We performed a retrospective cohort study among patients who underwent ultrasound examination for a cirrhosis-related indi...
119 CitationsSource
#1Hashem B. El-SeragH-Index: 19
#1H. El-SeragH-Index: 3
Last. Fasiha KanwalH-Index: 61
view all 7 authors...
2 CitationsSource
#1Sarah Berhane (University of Liverpool)H-Index: 15
#2Hidenori ToyodaH-Index: 63
Last. Philip J. Johnson (University of Liverpool)H-Index: 101
view all 25 authors...
Background & Aims GALAD and BALAD-2 are statistical models for estimating the likelihood of the presence of hepatocellular carcinoma (HCC) in individual patients with chronic liver disease and the survival of patients with HCC, respectively. Both models use objective measures, particularly the serum markers α-fetoprotein (AFP), AFP-L3, and des-γ-carboxyprothrombin. We aimed to validate these models in an international cohort of patients with HCC and assess their clinical performance. Methods We ...
108 CitationsSource
#1A. Blythe RyersonH-Index: 20
#2Christie R. EhemanH-Index: 24
Last. Betsy A. Kohler (North American Association of Central Cancer Registries)H-Index: 24
view all 16 authors...
and an incidence-based estimation of person-years of life lost because of the disease. By using NCHS multiple causes of death data, hepatitis C virus (HCV) and liver cancer-associated death rates were examined from 1999 through 2013. RESULTS: Among men and women of all major racial and ethnic groups, death rates continued to decline for all cancers combined and for most cancer sites; the overall cancer death rate (for both sexes combined) decreased by 1.5% per year from 2003 to 2012. Overall, in...
582 CitationsSource
Cited By43
Newest
#1Tung-Hung Su (NTU: National Taiwan University)H-Index: 28
#2Cheng-Yuan Peng (China Medical University (Taiwan))H-Index: 32
Last. Jia-Horng Kao (NTU: National Taiwan University)H-Index: 94
view all 0 authors...
BACKGROUND The risk of hepatocellular carcinoma (HCC) is reduced but not eliminated after nucleos(t)ide analogue (NA) therapy in chronic hepatitis B (CHB). We aimed to investigate the role of serum Prothrombin Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) and alpha-fetoprotein in predicting HCC and mortality in cirrhotic CHB patients at virological remission (VR) following NA therapy. METHODS Patients with CHB-related cirrhosis undergoing NA therapy from two medical centers in Taiwan ...
Source
#1Guillermo Carbonell (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 2
#1Guillermo Carbonell (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 3
Last. Bachir Taouli (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 59
view all 2 authors...
MR imaging has become a powerful tool for assessing liver disease and liver cancer; however, it entails complex, time-consuming, and costly protocols. Abbreviated MR imaging (AMRI) is emerging as a simpler, faster, and low-cost alternative to full-abdominal MR imaging protocols. Different AMRI approaches have been tested successfully in hepatocellular carcinoma detection and for assessment of diffuse liver disease. The most accurate, time-effective, and cost-effective protocol as well as the tar...
Source
#1Joeri Lambrecht (Charité)H-Index: 2
#2M Porsch-Özcürümez (RUB: Ruhr University Bochum)H-Index: 1
Last. Raphael Mohr (Charité)H-Index: 6
view all 8 authors...
(1) Background: Surveillance of at-risk patients for hepatocellular carcinoma (HCC) is highly necessary, as curative treatment options are only feasible in early disease stages. However, to date, screening of patients with liver cirrhosis for HCC mostly relies on suboptimal ultrasound-mediated evaluation and α-fetoprotein (AFP) measurement. Therefore, we sought to develop a novel and blood-based scoring tool for the identification of early-stage HCC. (2) Methods: Serum samples from 267 patients ...
Source
#2Kosh Agarwal (University of Cambridge)H-Index: 41
view all 2 authors...
(1) Background: Hepatocellular carcinoma (HCC) is an important cause of mortality in individuals with chronic hepatitis B infection, with screening of high-risk groups recommended in all major international guidelines. Our understanding of the risk factors involved has improved over time, encouraging researchers to develop models that predict future risk of HCC development. (2) Methods: A literature search of the PubMed database was carried out to identify studies that derive or validate models ...
Source
#1Devalingam Mahalingam (NU: Northwestern University)H-Index: 32
#2Leonidas Chelis (DUTH: Democritus University of Thrace)H-Index: 10
Last. Julia GrigorievaH-Index: 13
view all 16 authors...
Hepatocellular carcinoma (HCC) is one of the fastest growing causes of cancer-related death. Guidelines recommend obtaining a screening ultrasound with or without alpha-fetoprotein (AFP) every 6 months in at-risk adults. AFP as a screening biomarker is plagued by low sensitivity/specificity, prompting interest in discovering alternatives. Mass spectrometry-based techniques are promising in their ability to identify potential biomarkers. This study aimed to use machine learning utilizing spectral...
Source
Novel non-/minimally-invasive and effective approaches are urgently needed to supplement and improve current strategies for diagnosis and management of hepatocellular carcinoma (HCC). Overwhelming evidence from published studies on HCC has documented that multiple molecular biomarkers detected in body fluids and feces can be utilized in early-diagnosis, predicting responses to specific therapies, evaluating prognosis before or after therapy, as well as serving as novel therapeutic targets. Detec...
Source
#1Al B. Benson (NU: Northwestern University)H-Index: 121
#2Michael I. D’Angelica (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 98
Last. Susan Darlow (National Comprehensive Cancer Network)H-Index: 22
view all 36 authors...
The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcinoma). Due to the multiple modalities that can be used to treat the disease and the complications that can arise from comorbid liver dysfunction, a multidisciplinary evaluation is essential for determining an optimal treatment strategy. A multidisciplinar...
12 CitationsSource
#1Ming-Cheng Guan (Soochow University (Suzhou))H-Index: 1
#2Ming-Da Wang ('SMMU': Second Military Medical University)H-Index: 9
Last. Tian Yang ('SMMU': Second Military Medical University)H-Index: 27
view all 11 authors...
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths worldwide. The prognosis of patients with HCC remains poor largely due to the late diagnosis and lack of effective treatments. Despite being widely used, alpha-fetoprotein serology and ultrasonography have limited diagnostic performance for early-stage HCC. The emergence of omics strategies has contributed to significant advances in the development of non-invasive biomarkers for the early diagnosis of HCC includi...
Source
#1Agostino Colli (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)H-Index: 1
#1A. Colli (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)H-Index: 6
Last. Giovanni Casazza (University of Milan)H-Index: 32
view all 7 authors...
BACKGROUND Hepatocellular carcinoma (HCC) occurs mostly in people with chronic liver disease and ranks sixth in terms of global instances of cancer, and fourth in terms of cancer deaths for men. Despite that abdominal ultrasound (US) is used as an initial test to exclude the presence of focal liver lesions and serum alpha-foetoprotein (AFP) measurement may raise suspicion of HCC occurrence, further testing to confirm diagnosis as well as staging of HCC is required. Current guidelines recommend s...
3 CitationsSource
#1Daniel GehH-Index: 2
#2Quentin M. AnsteeH-Index: 64
Last. Helen L. ReevesH-Index: 34
view all 3 authors...
Due to an increase in the obesity-associated metabolic syndrome of epidemic proportions, nonalcoholic fatty liver disease (NAFLD) is becoming a leading cause of hepatocellular carcinoma (HCC) in western countries. This presents added challenges, as NAFLD-associated HCC tends to present at an advanced stage in older patients with co-morbidities. Their prognosis is generally poor with the benefits of standard therapies less certain. The pathogenesis of NAFLD-associated HCC is multifactorial and no...
Source